CAL-4
Asthma
Key Facts
About Calyxha Biotechnologies
Calyxha Biotechnologies is a preclinical-stage biotech leveraging a computational discovery platform to develop novel small molecule anti-inflammatory drugs. Its lead asset, CAL-4, is a calixarene-based compound designed to mimic heparan sulfate, aiming to provide steroid-like efficacy without the associated side-effect pathways. Initially targeting asthma via inhalation, CAL-4 is slated for clinical entry in 2025, with potential expansion into COPD, neurodegenerative diseases, and allergy. The company is led by a small, experienced team of entrepreneurs and scientists.
View full company profileAbout Calyxha Biotechnologies
Calyxha Biotechnologies is a preclinical-stage biotech leveraging a computational discovery platform to develop novel small molecule anti-inflammatory drugs. Its lead asset, CAL-4, is a calixarene-based compound designed to mimic heparan sulfate, aiming to provide steroid-like efficacy without the associated side-effect pathways. Initially targeting asthma via inhalation, CAL-4 is slated for clinical entry in 2025, with potential expansion into COPD, neurodegenerative diseases, and allergy. The company is led by a small, experienced team of entrepreneurs and scientists.
View full company profileAbout Calyxha Biotechnologies
Calyxha Biotechnologies is a preclinical-stage biotech leveraging a computational discovery platform to develop novel small molecule anti-inflammatory drugs. Its lead asset, CAL-4, is a calixarene-based compound designed to mimic heparan sulfate, aiming to provide steroid-like efficacy without the associated side-effect pathways. Initially targeting asthma via inhalation, CAL-4 is slated for clinical entry in 2025, with potential expansion into COPD, neurodegenerative diseases, and allergy. The company is led by a small, experienced team of entrepreneurs and scientists.
View full company profileAbout Calyxha Biotechnologies
Calyxha Biotechnologies is a preclinical-stage biotech leveraging a computational discovery platform to develop novel small molecule anti-inflammatory drugs. Its lead asset, CAL-4, is a calixarene-based compound designed to mimic heparan sulfate, aiming to provide steroid-like efficacy without the associated side-effect pathways. Initially targeting asthma via inhalation, CAL-4 is slated for clinical entry in 2025, with potential expansion into COPD, neurodegenerative diseases, and allergy. The company is led by a small, experienced team of entrepreneurs and scientists.
View full company profileTherapeutic Areas
Other Asthma Drugs
| Drug | Company | Phase |
|---|---|---|
| Technegas® for Asthma | Cyclomedica | Phase 2 |
| Asthma Candidate | Teva | Phase 3 |
| Montelukast Amorphous Form | Morepen Laboratories | Phase-2 |
| Chitinase Inhibitor | Lead Discovery Siena | Discovery |
| RIG-101 | RIGImmune | Pre-clinical |
| SKB378 | Klus Pharma | Phase 1 |
| Asthma Clinical Trials | American Health Research | Not Disclosed |
| Advanced Asthma Products | Polpharma | Not Disclosed |
| Solrikitug | Uniquity Bio | Phase 2 |
| Asthma Trial | Science 37 | Phase 3 |
| Digital Biomarker for Asthma | electronRx | Early Development |
| Flutiform | KYORIN Pharmaceutical | Marketed |